Company profile for Ultragenyx Pharmaceutical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are no approved therapies. ...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are no approved therapies. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
60 Leveroni Court Novato, CA 94949
Telephone
Telephone
+1-415-483-8800
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/19/3208745/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
19 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193949/20739/en/Ultragenyx-to-Participate-in-Investor-Conferences-in-December.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/21/3193031/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
21 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180883/20739/en/Ultragenyx-Reports-Third-Quarter-2025-Financial-Results-and-Corporate-Update.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180804/20739/en/Ultragenyx-Announces-Sale-of-a-Portion-of-Future-North-American-Royalties-on-Crysvita-burosumab-for-400-Million-to-OMERS-Life-Sciences.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177366/20739/en/Ultragenyx-Announces-First-Patient-Dosed-in-Aurora-Study-Evaluating-GTX-102-in-Additional-Angelman-Syndrome-Genotypes-and-Age-Groups.html

GLOBENEWSWIRE
30 Oct 2025

ABOUT THIS PAGE

Contact Ultragenyx Pharmaceutical and get a quotation

Ultragenyx Pharmaceutical is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Triheptanoin bulk with DMF offered by Ultragenyx Pharmaceutical

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty